Proton radiotherapy for mediastinal Hodgkin lymphoma: theoretical background and clinical experience

Dědečková K.1,2, Zapletalová S.1, Móciková H.1,3, Ghahérová L.1, Marková J.1, Andrlík M.1, Vondráček V.1, Kaliská L.1, Kubeš J.1,2

1. Proton Therapy Center Czech, Praha, Czech Republic
2. Department of Oncology, University Hospital Motol and 2nd Faculty of Medicine, Praha, Czech Republic
3. Internal Hematology Clinic, Faculty Hospital Karlovarské Vinohrady and 3rd Faculty of Medicine, Praha, Czech Republic

INTRODUCTION

Radiotherapy plays an important role in the treatment of Hodgkin lymphoma (HL). RT omission is associated with the suboptimal results for significant group of patients. The use of the most safe radiotherapy (RT) technique is crucial. Proton therapy (PT) is a modern radiation technique based on the use of particles. Compared to conventional radiotherapy, PT allows higher protection of healthy tissues. This is associated with lower risk of the significant acute toxicity (radiation pneumonitis, severe dysphagia) and late toxicity (cardiovascular disease, secondary malignancies).

METHODS

Between May 2013 and December 2019, 129 patients (pts) received mediastinal PT via pencil beam scanning (PBS) technique. Seventy-three patients were analyzable for acute toxicity and treatment response due the sufficient long follow-up. Median follow-up was 44.5 months (23.4-79.7 months), median age at the time of RT was 32.2 years (18.5-79.2 years). Dose median was 30 GyE (20-40 GyE). RT for PET positive disease had 13 pts. Deep inspiration breath hold (DIBH) technique was used in 57 patients, others under free breathing condition after 4D control.

<table>
<thead>
<tr>
<th>Characteristic of patients (n=73)</th>
<th>Males/females [pts.]</th>
<th>Age in time of RT median [years]</th>
<th>RT volume [pts.]</th>
<th>Median follow-up [months]</th>
<th>RT on PET neg/PET positive disease/unknown [pts.]</th>
<th>RT in DIBH/FB [pts.]</th>
<th>Median dose [GyE]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males/females [pts.]</td>
<td>28/45</td>
<td>32.2 (18.5-79.2)</td>
<td>Involved field</td>
<td>9</td>
<td>56/13/4</td>
<td>57/16</td>
<td>30 (20-40)</td>
</tr>
<tr>
<td>Age in time of RT median [years]</td>
<td>32.2 (18.5-79.2)</td>
<td>RT volume [pts.]</td>
<td>15</td>
<td>49</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median follow-up [months]</td>
<td>44.5 (23.4-79.7)</td>
<td>RT on PET neg/PET positive disease/unknown [pts.]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RT in DIBH/FB [pts.]</td>
<td>57/16</td>
<td>Median dose [GyE]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RESULTS

Treatment results
Seventy-two (98.2%) pts have achieved local control, 1 pt with unproven in-field and distant progression (declines all medical procedures after restaging PET/CT, alive 27 months after RT completion without symptoms of HL). Seventy-one pts (97.2%) alive in complete remission, with 1 pt salvaged via allo-SCT, 1 pt progressed on salvage therapy, 1 pt with unknown status as mentioned above. There was observed latency in metabolic response in some patients (6-12 months after RT completion), mostly in pts with necrotic bulky mediastinal disease.

Toxicity
Acute toxicity was mild, mostly dysphagia, radiodermatitis, transient xerostomia, dysgeusia. No case of symptomatic pneumonitis was observed. No patient required growth factor application or blood supplementation. To date, we hadn’t case of Lhermitt’s syndrome or late pulmonary toxicity.

CONCLUSIONS

PT offers safe possibility for mediastinal RT. PT via PBS in deep inspiration breath hold is to be the most sparing radiotherapy approach for mediastinal lymphoma. Our clinical data support this statement.